Key result
Treatment with open radical nephrectomy followed by six cycles of docetaxel and gemcitabine adjuvant chemotherapy resulted in no signs of recurrence at 9 months in a patient with primary renal synovial sarcoma.
Why the study?
Primary synovial sarcoma of the kidney is a rare renal sarcoma that often presents atypically, and clear guidelines regarding appropriate treatment are lacking.
Case Report (n=1)
No
Treatment with docetaxel and gemcitabine after open radical nephrectomy showed promising results with no recurrence at 9 months in a rare case of primary renal synovial sarcoma presenting with haemorrhagic shock.
Answers are grounded in this paper and cite their sources.
Renal synovial sarcoma may cause acute hemorrhagic shock; this Level 5 case leaves optimal management strategies open.
Primary synovial sarcoma (PSS) of the kidney is considered the rarest type of all renal sarcomas with specific chromosomal translocation t (X; 18) (p11.2; q11.2). We report the case of a 65-year-old man with no medical conditions who presented to the emergency department with sudden severe right flank pain associated with haemodynamic instability and haemorrhagic shock. Computed tomography (CT) of the abdomen and pelvis revealed a right renal mass. A right open radical nephrectomy was performed. Histopathology revealed a monophasic synovial sarcoma. The patient received six cycles of docetaxel and gemcitabine as adjuvant chemotherapy. No sign of recurrence was seen on a follow-up CT urogram. This rare tumour often presents atypically, and clear guidelines regarding appropriate treatment are lacking. Our case showed that treatment with docetaxel/gemcitabine after an open radical nephrectomy is promising.
No takes yet. Share an insight, caveat, or question.
Alzahrani et al. (2021) conducted a case report in Primary Renal Synovial Sarcoma (n=1). Open radical nephrectomy and adjuvant docetaxel/gemcitabine was evaluated on Tumor recurrence. Treatment with open radical nephrectomy followed by six cycles of docetaxel and gemcitabine adjuvant chemotherapy resulted in no signs of recurrence at 9 months in a patient with primary renal synovial sarcoma.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: